MVP and ovarian carcinoma: Our finding adds to several clinical studies reporting overexpression of LRP at diagnosis as an independent predictor for clinical outcome and/or chemotherapy failure, for example, in acute myeloid leukaemia (List et al, 1996; Borg et al, 1998; Filipits et al, 1998,2000), multiple myeloma (Raaijmakers et al, 1998; Filipits et al, 1999), stage III–IV ovarian carcinoma (Izquierdo et al, 1995), and locally advanced bladder cancer (Diestra et al, 2001).